Akums Drugs and Pharmaceuticals Limited · NSE:AKUMS

Akums Drugs and Pharmaceuticals — Q2 FY2027 Earnings Presentation

22 slides from Akums Drugs and Pharmaceuticals's earnings presentation, Nov 2, 2026

  1. Slide 1: Exchange cover letter for investor presentation

    Ref: Akums/Exchange/2026-27/60 November 02, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051

  2. Slide 2: Q2 FY 26-27 Investor Presentation

    Q2 FY 26-27 Investor Presentation November 2026

  3. Slide 3: Disclaimer

    Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co

  4. Slide 4: Managing Directors' Message

    Managing Directors’ Message Dear Investors We are pleased to announce the results for Q2 FY27 and H1 FY27. During Q2, we enhanced the results achieved during Q1. During Q2, the revenue grew by more than 30% and EBITDA more than doubled YoY. Even sequentially i.e. QoQ, the revenue growth was at an im

  5. Slide 5: More than Two Decades' Legacy of Expertise, Experience & Trust

    More than Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to Plant 1 ,2 & 3 received EU- manufacturing site for Parabolic Drugs to Launched Aku

  6. Slide 6: Technologically Advanced Manufacturing Capabilities (1/2)

    Technologically Advanced Manufacturing Capabilities (1/2) Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar YEAR 2004 2007 2007 2010 2010 2010 2014 CAPACITY¹ 649 15 39 264 6 269 2,635 Ayurvedic / CAPABILITY General General General Hormonal Cosmetics Nutraceuticals General DOSAG

  7. Slide 7: Technologically Advanced Manufacturing Capabilities (2/2)

    Technologically Advanced Manufacturing Capabilities (2/2) PHOTO PHOTO Location Haridwar Kotdwar Baddi Haridwar Roorkee Noida Baddi# YEAR 2014 2021 2023 2024 2026 2026 2027 CAPACITY¹ 732 17 392 41 13 7 - β-lactams & Penem CAPABILITY steroids anti-infective General General Cosmeceuticals Cosmeceutical

  8. Slide 8: Financial Performance Highlights

    Q2/H1 FY 27 Financial Performance Highlights 7

  9. Slide 9: Key drivers as well as their trends during Q2 FY27

    Key drivers as well as their trends during Q2 FY27 Key drivers and their impact on Akums’ performance Marketing Strong CDMO API segment API prices saw segments volume growth continues on its an increase in profitability momentum path to Q2 improved continues profitability sequentially International

  10. Slide 10: Q2 FY27 Performance Highlights

    Q2 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 224 cr 115 cr CDMO 83.1% 1,371 cr 121 cr 54 cr 1,050 cr 16.3% 8.4% Domestic Branded Formulation 9.8% 11.6% 5.1% Total Income EBITDA (including PAT International Branded Formulation 3.3% Total

  11. Slide 11: H1 FY27 Performance Highlights

    H1 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 429 cr 216 cr CDMO 82.9% 2,568 cr 121 cr 54 cr 1,050 cr 16.7% 8.4% Domestic Branded Formulation 9.9% 11.6% 5.1% Total Income EBITDA (including PAT International Branded Formulation 3.1% Total

  12. Slide 12: Profit and Loss Statement

    Profit and Loss Statement Particulars (Rs Cr) Q2 FY27 Q2 FY26 Y-O-Y (%) Q1 FY27 Q-O-Q (%) H1 FY 27 H1 FY 26 Y-O-Y (%) FY26 Revenue 1,342 1,018 31.9% 1,167 15.1% 2,509 2,042 22.9% 4,359 COGS 767 593 29.4% 645 18.8% 1,412 1,174 20.2% 2,514 GP Margin % 42.9% 41.8% 44.7% 43.7% 42.5% 42.3% Employee Expen

  13. Slide 13: Quarterly Performance Trends

    Quarterly Performance Trends Revenue (INR Cr.) EBITDA (INR Cr) PAT (INR Cr) Margin % Margin % 9.3% 12.7% 13.1% 15.0% 14.5% 4.1% 5.7% 6.8% 8.4% 8.4% 31.9% 106.1% 168.3 % 1,342 1,160 1,158 1,167 195 115 1,018 175 101 147 152 81 68 94 43 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q3 FY26 Q4 FY26 Q

  14. Slide 14: HY Performance Trends

    HY Performance Trends Revenue (INR Cr.) EBITDA (INR Cr) PAT (INR Cr) Margin % Margin % 12.0% 10.4% 10.9% 12.9% 14.7% 6.2% 10.3% 5.1% 6.2% 8.4% 22.9% 65.3% 100.7 % 2,509 369 2,317 216 216 2,052 2,066 2,042 299 245 149 215 223 128 107 H1 FY25 H2 FY25 H1 FY26 H2 FY26 H1 FY27 H1 FY25 H2 FY25 H1 FY26 H2

  15. Slide 15: Half-Yearly Performance Highlights

    Half-Yearly Performance Highlights Working Capital Days Operating Cash Flow (INR Cr)# Return Ratios* Net WC Adj OCF/EBITDA % 91 105 98 88.7% 43.5% 69.2% 22.2% 1,181 117 1,152 19.4% 110 100 14.6% 82 13.1% 13.0% 14.3% 76 12.2% 67 67 71 63 256 256 7.7% 227 6.8% 198 H1 FY26 FY 26 H1 FY 27 H1 FY26 FY26 H

  16. Slide 16: Revenue and Margin Deep-Dive – Quarterly

    Revenue and Margin Deep-Dive – Quarterly Revenue (INR Cr.) EBITDA % • Revenue growth driven by CDMO • Other exp and employee exp benefitted from operating leverage • International branded formulation showed healthy growth on weak base • GM improvement led by CDMO and API segments • Reduction in API

  17. Slide 17: Revenue and Margin Deep-Dive – Half Yearly

    Revenue and Margin Deep-Dive – Half Yearly Revenue (INR Cr.) EBITDA % • Revenue growth driven by CDMO • Other exp and employee exp benefitted from operating leverage • International branded formulation showed healthy growth on lower base • GM improvement led by CDMO and API segments • Reduction in A

  18. Slide 18: Segmental Quarterly Performance

    Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue QoQ 15.6% YoY 38.6% QoQ 14.4% YoY 8.2% QoQ 26.7% YoY 95.2% QoQ 10.1% YoY -5.4% QoQ -9.1% YoY -35.3% 1,115 132 24 44 964 122 115 804 44 23 35

  19. Slide 19: Segmental HY Performance

    Segmental HY Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue YoY 28.5% YoY 7.8% YoY 36.2% YoY -7.4% YoY -32.5% 2,079 247 89 229 48 1,618 78 60 57 44 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 F

  20. Slide 20: Annexures

    Annexures ‘bel lids

  21. Slide 21: Abbreviations and Definitions

    Abbreviations and Definitions Abbreviations Definitions • CDMO: Contract development and manufacturing organization • Net WC: Debtor days + Inventory days – Creditor days • API: Active Pharmaceutical Ingredient • ROE: PAT/ Total Equity • EBITDA: Earnings before interest, depreciation and tax • ROCE:

  22. Slide 22: Thank You

    Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: [email protected]/[email protected] 21

Akums Drugs and Pharmaceuticals — Q2 FY2027 Earnings Presentation on 6ix